Validation gaps in Medicine

Representative open questions

Showing 30 of 597 — one per source paper, highest-quality first.

• Regulatory T cell therapies: biological foundations, engineering strategies, and clinical translation (2026) · doi

  The EIGHT Treg study lacks a control group for conventional induction immunosuppression, making it difficult to assess the efficacy of CD8+ Tregs in preventing renal graft rejection.

• Heart-brain axis pathophysiological understanding and clinical impact (2026) · doi

  Left ventricular dysfunction as a determinant of functional outcomes in acute ischemic stroke patients (reference 108) requires prospective validation with echocardiographic assessment and neurological outcome correlation in larger cohorts to establish predictive thresholds.

• The impact of traumatic injury on the respiratory system; a narrative review of injury-associated and clinically-induced mechanisms of trauma-associated pneumonia (2026) · doi

  Machine learning approaches have been applied to predict pneumonia in flail chest patients, but external validation of these predictive models across different trauma populations and prospective testing in clinical practice settings is lacking, limiting their generalizability and clinical utility.

• Digitizing Dementia-Friendly Environments (DFEs): the application of digital technologies in promoting inclusive spaces (2026) · doi

  Personalized onboarding protocols and low-step-count interaction flows for VR/AR and assistive robotics in dementia contexts lack comparable outcome metrics across studies. Research should develop and validate standardized usability assessment frameworks that measure intuitive interaction design effectiveness for dementia patients with varying cognitive abilities, enabling consistent evaluation across different technology implementations.

• FDG-PET/CT based small volume accelerated immuno chemoradiotherapy in locally advanced NSCLC (PACCELIO) – a randomized, open-label, multicenter phase II trial protocol (2026) · doi

  The synergistic effects of combining hypofractionated, accelerated dose delivery with target volume reduction in locally advanced NSCLC have not been directly quantified in randomized trials. The biologically effective dose calculations and their relationship to both acute/late toxicity reduction and immunotherapy advancement rates require prospective validation with organ-at-risk dose constraints.

• From organelles to therapy: rethinking combined hepatocellular-cholangiocarcinoma (2026) · doi

  Organelle phenotypes must be systematically integrated with clinical features and patient outcomes in cHCC-CCA cohorts to establish whether organelle biology can predict treatment response and prognosis, enabling precision medicine approaches that match organelle-targeting agents to individual tumor biology.

• Managing Spinal Muscular Atrophy: A Look at the Biology and Treatment Strategies (2025) · doi

  SMN2 copy number and variants have been shown to modify SMA phenotype, but the genotype-phenotype correlations in patients with complex SMN2 structural variations and deletion junctions require larger cohort validation beyond existing studies to establish predictive biomarkers for disease progression.

• Integration of biomedical imaging and sensing technologies with AI-IoT for Materiovigilance and predictive modeling of stillbirth risk in maternal-fetal health monitoring (2026) · doi

  AI model generalization and repeatability are compromised by data heterogeneity across different sensor types, maternal conditions, and gestational stages. Longitudinal prospective cohort studies involving multiple populations are required to test AI-IoT algorithms and guarantee scalability across varied maternal-fetal monitoring scenarios.

• Neurosurgery as an immune anchor point: a translational framework for perioperative immunoengineering (2026) · doi

  The paper identifies meningeal immunity and neuroinflammation-associated neurotoxicity from immune checkpoint inhibitor therapy but does not specify mechanistic predictors for identifying patients at high risk of severe neurological adverse events. Biomarker profiling of clonally expanded effector CD4+ cytotoxic T lymphocytes and their correlation with perioperative autonomic nervous system imbalance requires prospective validation in neurosurgical cohorts.

• The neuro-immune axis in preeclampsia: from the maternal-fetal interface to systemic dysregulation (2026) · doi

  The paper identifies that different preeclampsia subtypes (acute neurovascular instability versus placental angiogenic dysfunction) should exhibit distinct autonomic imbalance signatures, but does not specify which standardized autonomic biomarkers should be measured (heart rate variability indices, baroreceptor sensitivity, sympathetic/parasympathetic tone ratios) or establish cutoff thresholds for distinguishing PE subtypes.

• The use of artificial intelligence based modelling techniques in One Health-related infectious disease studies in Sub-Saharan Africa: a review (2026) · doi

  AI-based One Health infectious disease models in Sub-Saharan Africa currently lack systematic validation using external datasets from independent geographic regions within SSA; cross-validation and sensitivity analyses across West and Central African contexts remain largely absent from the literature.

• Autologous Platelet Concentrates in Sports Medicine: Mechanisms of Tissue Regeneration and Clinical Applications – A Narrative Review (2026) · doi

  The biological rationale for tissue-specific efficacy of different autologous platelet concentrate formulations (leukocyte-rich PRP, leukocyte-poor PRP, PRF, i-PRF) has not been adequately tested across a standardized panel of musculoskeletal tissues (tendon, ligament, cartilage, muscle) with matched preparation variables and outcome assessment endpoints.

• What is The Effect of Early Enteral Nutrition on Mortality in Critically Ill Patients Receiving Vasopressor Support? : A Systematic Review (2026) · doi

  The paper documents inconsistent mortality outcomes across disease-specific cohorts (COVID-19 pneumonia showing benefits, septic shock showing variable results, ARDS and traumatic brain injury requiring tailored approaches), yet no comparative effectiveness trials have systematically evaluated organ-dysfunction-specific feeding strategies (dose, timing, route) to determine risk-benefit profiles for ARDS, acute pancreatitis, and traumatic brain injury patients on vasopressor support.

• Decision-ready evidence for vital pulp therapy: a network meta-analysis of bioactive materials in mature permanent teeth (2026) · doi

  The network meta-analysis stratified mature permanent teeth but did not separately analyze outcomes for specific tooth types (molars vs. premolars vs. incisors) or by caries depth/location, which may differentially affect hemostasis control and restoration margins in pulpotomy procedures. Future RCTs should report subgroup analyses of absolute success rates for bioactive materials disaggregated by tooth type and caries extent.

• Exercise benefits in metabolism on cardiovascular disease (2026) · doi

  Although extracellular vesicles have been shown to mediate tissue crosstalk during exercise, the specific composition and functional role of exercise-induced extracellular vesicles in improving cardiovascular metabolic outcomes across different cardiovascular disease phenotypes and exercise prescriptions requires systematic investigation.

• What is the diagnostic accuracy of different clinical diagnostic criteria (Rotterdam, NIH, and Androgen Excess Society) for identifying polycystic ovary syndrome in women of reproductive age? : A Systematic Review (2026) · doi

  Phenotype-specific diagnostic performance reveals that AMH levels and ultrasonographic markers (follicle count, ovarian volume) show satisfactory accuracy only for Rotterdam phenotype A (hyperandrogenism + oligo-ovulation + PCOM), but fair validity for phenotypes B, C, and D; phenotype-stratified diagnostic thresholds have not been systematically developed or validated across different ethnic populations.

• Deep learning-based multimodal prediction of chronic kidney disease stage (2026) · doi

  The study evaluates the multimodal model using 10-fold cross-validation but does not report temporal validation or prospective validation performance, which is critical for assessing whether the deep learning model trained on historical CKD patient data can accurately predict stages in future patient cohorts with potentially evolving clinical presentations.

• Effectiveness of screening modalities for early detection of diabetic retinopathy: a systematic review and meta-analysis of tele-ophthalmology, AI-based tools, and conventional methods (2026) · doi

  AI-based DR detection algorithms have achieved high sensitivity in controlled settings but lack head-to-head randomized controlled trials directly comparing standalone deep learning tools, automated AI systems, and human grader performance in real-world primary care populations.

• The Relationship between a History of Cesarean Section and The Incidence of Placenta Accreta : A Systematic Review (2026) · doi

  The Moradan et al. Iranian study found no significant differences in accreta between second versus more than two cesarean sections, contradicting most other literature. This discordance may reflect population-specific factors (surgical techniques, infection rates, tissue healing characteristics) in Iranian tertiary settings. Replication of this comparison using larger sample sizes and multicenter cohorts in both high-income and lower-income healthcare systems is needed.

• A systematic review of sample size determination in Bayesian randomized clinical trials: full Bayesian methods are rarely used (2026) · doi

  The review documents extensive use of hybrid approaches across diverse outcome types (binary, continuous, ordinal, survival, joint, count, multiple endpoints), but does not systematically compare the performance or appropriateness of hybrid versus full Bayesian sample size methods across these specific outcome data structures. Research is needed to establish when hybrid methods are justified versus when full Bayesian approaches would be superior for each outcome type.

• Unveiling the relationship of the comorbidity between depression and type 2 diabetes mellitus: a macro analysis and micro interpretation (2026) · doi

  The reciprocal intervention model for depression and T2DM comorbidity—regulating metabolic status through psychological intervention or alleviating emotional disorders through blood glucose control—requires high-quality evidence through cross-border collaborative trials. Specific clinical trial designs testing this bidirectional treatment approach across different healthcare systems remain underdeveloped.

• A behaviour and disease model of testing and isolation (2026) · doi

  The model implements idealised testing conditions with no delays in test accessibility, availability, or supply constraints. Future modelling should incorporate empirical data on test supply limitations and investigate the cascading effects on infectious prevalence when individuals cannot access tests and do not self-isolate, as well as the negative feedbacks on testing uptake for future infection episodes.

• Bioactive and Ion-releasing materials in minimum intervention dentistry: a clinical pathway from prevention to restorative treatment (2026) · doi

  Diagnostic innovations such as fluorescent intraoral cameras demonstrate clinical benefits in caries detection but historically receive only moderate evidence ratings; standardised comparative studies are needed to establish their diagnostic accuracy and clinical value relative to conventional detection methods in minimum intervention dentistry.

• Artificial intelligence approaches to predicting treatment non-adherence in chronic diseases: a narrative review (2026) · doi

  External validation of AI-based adherence prediction models across diverse healthcare contexts and patient populations is lacking. Rigorous prospective trials demonstrating clinical impact must be conducted across heterogeneous healthcare systems, disease populations, and geographic settings to establish generalizability before widespread adoption in chronic disease management.

• Evidence-based approaches for Empty Nose Syndrome management: a systematic review highlighting current treatments and future directions (2026) · doi

  Outcome measures for Empty Nose Syndrome management are not consistently defined, validated, or reliably applied across studies, creating heterogeneity that hinders comparison of surgical, regenerative, and pharmacological-cognitive treatment efficacy across different patient populations.

• Human-centered Perspectives on a Clinical Decision Support System for Intensive Outpatient Veteran PTSD Care (2026) · doi

  Future CDSS design for veteran PTSD care must explicitly incorporate and evaluate patient privacy, data security, and trust factors in the context of passive tracking of health data and sPGD (standardized patient-generated data). The ethical implications of implementing these tracking mechanisms within a clinical decision support system for manualized psychotherapy have not been empirically tested with veteran populations.

• Multimodal artificial intelligence in urologic precision oncology: from algorithm to translational medicine (a systemized narrative review) (2026) · doi

  Multimodal AI for diagnosis of clinically significant prostate cancer has been evaluated in multicenter studies (reference 57), but longitudinal validation of AI-derived predictions against long-term biochemical recurrence, metastasis-free survival, and castration resistance endpoints in independent prospective cohorts is absent.

• GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders (2026) · doi

  Clinical translation of GlyT1 inhibition efficacy from preclinical models (rats and monkeys) to human trials remains incomplete. Optimal dosing regimens, long-term safety profiles, and efficacy across diverse populations for schizophrenia, cerebral ischemia, Alzheimer's disease, and addiction disorders have not been fully established in rigorous clinical settings.

• Quercetin in metabolic diseases: mechanisms, therapeutics, and multidimensional frontiers (2026) · doi

  While quercetin liposomes, phytosomes, nanoemulsions, and hydrogel delivery systems have been individually evaluated for improved bioavailability in metabolic disease models, comparative efficacy studies directly contrasting these nanoencapsulation approaches in the same diabetic or obesity cohorts are absent. Head-to-head comparison of succinyl chitosan-stabilized liposomes versus whey protein isolate hydrogels versus lecithin phytosomes in streptozotocin-induced or db/db diabetic models is needed to establish which delivery system optimizes quercetin bioavailability and therapeutic outcomes.

• Lipidomics and machine learning revealing dysregulation of specific triacylglycerol and phosphatidylglycerol as hub lipids associated with fetal growth in gestational diabetes mellitus (2026) · doi

  The machine learning model integrating multidimensional indicators (lipids, TP, RDW, clinical parameters) should be prospectively evaluated in a second-trimester pregnant cohort to assess its earlier risk identification capability and validate whether the identified lipid biomarkers enable clinical intervention before GDM diagnosis.